:) on the title. you rockin' today
Things that make you question the SEC
News today on NKTR
Nektar's Cancer Drug Shows Reduced Response Rate In Bladder Cancer
Abstract submitted by Nektar Therapeutics (NASDAQ: NKTR) for presentation at the ASCO Genitourinary Cancers Symposium showed that data from the PIVOT-02 Phase 1/2 Study that evaluated its NKTR-214 in combination with Bristol-Myers Squibb's Opdivo for metastatic urothelial cancer, produced a 48 percent overall response rate compared to a 60 percent response rate reported in June. The company will present detailed results at the symposium Feb. 15.
https://finance.yahoo.com/news/daily-biotech-pulse-nash-disappointment-130455631.html
https://www.secform4.com/insider-trading/906709.htm
chek'ed and congrats
working on that anon